CD33 and acute myeloid leukemia: In this direction, CAR T cells targeting antigens on LSC (CD123) and AML blasts (CD33) show relevant preclinical efficacy [78], and dual CAR T cells targeting CD123, CD33 or CLL1 are being tested in clinical trials (NCT03795779, NCT04156256 and NCT04010877) with promising results reported for CLL1-CD33 CAR T cells (NCT03795779) [79].